Press release
Fabry Disease Treatment Market Projected to Reach USD 5,321.12 Million by 2034, Growing at a CAGR of 6.9%
Polaris Market Research has recently published its latest research report titled, "Fabry Disease Treatment Market Size, Share, & Industry Analysis Report By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, By Region - Market Forecast, 2025-2034."
The report analyzes the market to register a CAGR of 6.9% during 2025-2034. The market was valued at USD 2,727.85 million in 2024 and is projected to grow to USD 5,321.12 million by 2034.
Get Exclusive Sample Pages of This Report: https://www.polarismarketresearch.com/industry-analysis/fabry-disease-treatment-market/request-for-sample
Market Introduction
Fabry disease treatment focuses on managing symptoms, slowing disease progression, and improving quality of life for individuals affected by this inherited lysosomal storage disorder. Fabry disease results from a deficiency or malfunction of the enzyme alpha-galactosidase A. The deficiency or malfunction of the enzyme leads to the accumulation of a fatty substance called globotriaosylceramide (GL-3) in blood vessels and organs. One of the primary treatment approaches is enzyme replacement therapy (ERT), where synthetic versions of the missing enzyme are administered intravenously to help clear GL-3 buildup. Another option is chaperone therapy, such as migalastat, which stabilizes the patient's own dysfunctional enzyme and enhances its activity. In addition, supportive treatments such as pain management and medications to control kidney function, heart issues, and strokes play a key role.
Market Growth Drivers
Adoption of Personalized Medicine: The rising adoption of personalized medicine presents a transformative role in the treatment of personalized care. Personalized medicine involves tailoring medical treatment to the genetic profile and disease characteristics of the specific individual. The shift towards personalized care is improving diagnostics and supports better disease management across diverse patient subgroups.
Expansion of Reimbursement Policies: The evolution of reimbursement frameworks is significantly fueling the demand for therapies that target rare diseases. The financial implications of treatment, which often involves prolonged or lifelong administration, place considerable strain on both patients and healthcare systems. Government bodies, policymakers, and insurers are responding to this by increasingly adopting comprehensive models to account for the distinct economic dynamics of rare diseases. Thus, the expansion of reimbursement policies is fueling the Fabry disease treatment market expansion.
Request for a Discount on this Report Before Purchase: https://www.polarismarketresearch.com/industry-analysis/fabry-disease-treatment-market/request-for-discount-pricing
Market Key Players
The Fabry disease treatment market exhibits a competitive landscape shaped by continuous advancements in therapeutic approaches. Pharmaceutical companies compete by developing enzyme replacement therapies (ERTs) and gene therapies that target the underlying alpha-galactosidase A deficiency. A few of the major market participants include:
• Amicus Therapeutics, Inc.
• CANbridge Life Sciences Ltd.
• Chiesi Farmaceutici S.p.A.
• Idorsia Pharmaceuticals Ltd.
• ISU ABXIS Co., Ltd.
• JCR Pharmaceuticals Co., Ltd.
• Protalix Biotherapeutics Inc.
• Sangamo Therapeutics, Inc.
• Sanofi
• Takeda Pharmaceutical
Fabry Disease Treatment Industry Developments
• March 2024: CENTOGENE expanded its partnership with Takeda to enhance access to genetic testing for patients with lysosomal storage disorders (LSDs), including Fabry disease. The collaboration focuses on advancing genetic diagnostics to ensure accurate and timely testing, improving disease management outcomes.
• March 2022: JCR Pharmaceuticals and Sumitomo Dainippon Pharma entered into a marketing alliance in Japan for Agalsidase Beta BS I.V. infusion, a treatment designed specifically for managing Fabry disease.
• January 2022: ISU ABXIS signed a licensing agreement with NPO Petrovax Pharm in Russia for "Fabagal," a therapeutic product developed for the treatment of Fabry disease.
Segmental Analysis
By Route of Administration Outlook (Revenue USD Million, 2020-2034)
• Intravenous Route
• Oral Route
By Therapy Outlook (Revenue USD Million, 2020-2034)
• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Therapy (SRT)
• Others
By Distribution Channel Outlook (Revenue USD Million, 2020-2034)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Explore The Complete Comprehensive Report Here: https://www.polarismarketresearch.com/industry-analysis/fabry-disease-treatment-market
Regional Overview
Asia Pacific led the global market in 2024. The regional market dominance is primarily fueled by the growing awareness of rare genetic disorders and the expansion of diagnostic infrastructure in the region. Initiatives by government bodies and healthcare authorities have significantly boosted the adoption of life-saving drugs for Fabry disease treatment, positively impacting market development.
The presence of a robust clinical infrastructure and favorable regulatory frameworks fuels the market growth in North America. North America's well-established reimbursement ecosystem, which enables access to high-cost rare disease therapies, further fuels market expansion in the region.
More Trending Latest Reports by Polaris Market Research:
https://www.polarismarketresearch.com/industry-analysis/large-molecule-drug-discovery-outsourcing-market
https://www.polarismarketresearch.com/industry-analysis/asia-pacific-gaucher-disease-treatment-market
https://www.polarismarketresearch.com/industry-analysis/north-america-gaucher-disease-treatment-market
https://www.polarismarketresearch.com/industry-analysis/glp-1-receptor-agonist-market
https://www.polarismarketresearch.com/industry-analysis/glp-1-market
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fabry Disease Treatment Market Projected to Reach USD 5,321.12 Million by 2034, Growing at a CAGR of 6.9% here
News-ID: 4087580 • Views: …
More Releases from Polaris Market Research and Consulting
In Situ Hybridization Market Size Set to Hit USD 3,015.57 Million by 2034, Growi …
Polaris Market Research has released new insights into the In Situ Hybridization market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 1,546.93 million and is anticipated to grow to USD 3,015.57 million by…
Next Generation Sequencing Sample Preparation Market Size Set to Hit USD 16.57 B …
Polaris Market Research has released new insights into the Next Generation Sequencing Sample Preparation market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 4.09 billion and is anticipated to grow to USD 16.57…
Plastic Welding Equipment Market Projected to Reach USD 2.69 Billion by 2034 , R …
Polaris Market Research announces the release of its latest study on the Plastic Welding Equipment market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at USD 1.60 billion in 2024 and is expected to reach USD…
DNA Manufacturing Market Projected to Reach USD 21.82 Billion by 2034, Registeri …
Polaris Market Research announces the release of its latest study on the DNA Manufacturing market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at USD 5.59 billion in 2024 and is expected to reach USD 21.82…
More Releases for Fabry
U.S. Fabry Disease Market Size Report 2034
On April 28, 2025, Exactitude Consultancy., Ltd. released a research report titled "U.S. Fabry Disease Market". This report covers the global U.S. Fabry Disease market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
Top Factor Driving Fabry Disease Treatment Market Growth in 2025: Impact of Incr …
How Are the key drivers contributing to the expansion of the fabry disease treatment market?
The rising prevalence of renal diseases is expected to drive the growth of the Fabry disease treatment market. Renal diseases are becoming more prevalent due to genetic factors, lifestyle choices, and environmental influences. Fabry disease, which causes kidney dysfunction, is increasing and requires timely intervention. According to the Australian Bureau of Statistics, kidney disease affected 246,200…
Fabry Disease Market Trends Analysis 2030
Fabry disease is a rare X-linked lysosomal storage disorder. This patient has a deficiency in the enzyme alpha galactosidase, which progresses to organ failure. The development of fabry illnesses is mostly caused by abnormal accumulation of a certain fatty substance known as globotriaosylceramide. This aberrant buildup can be detected in the skin, eyes, heart, kidney, brain, gastrointestinal system, and central nervous system, among other body parts.
Galactosidase Alpha (GLA) is a…
Fabry Disease Market Pipeline 2019 Analysis and Developmental Stages
"Fabry Disease - Pipeline Insight, 2019” report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fabry Disease development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued…
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called…
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of…
